Waterstone Pharma is an international biopharmaceutical company primarily operating in China, dedicated to the discovery, development, and commercialization of innovative drugs targeting significant unmet medical needs, particularly in liver and gastrointestinal diseases. The company serves a global market and is backed by venture capital investments from renowned firms such as BAR Capital, CID Group, Orbimed, and Acorn Camps. Waterstone Pharma has established fully integrated capabilities spanning from research and development (R&D) to active pharmaceutical ingredient (API) and finished drug product manufacturing. The company generates revenue through the commercialization of its therapeutic products, including over forty marketed drugs in China, and is actively involved in clinical trials and preclinical stage antiviral research. Waterstone's strong management team boasts cross-border experience and expertise in drug discovery, regulatory affairs, and good manufacturing practices (GMP), ensuring a robust pipeline of novel therapeutics.

Keywords: biopharmaceutical, liver diseases, gastrointestinal diseases, innovative drugs, venture capital, R&D, API manufacturing, clinical trials, antiviral research, GMP.